x min read

Watch List Highlights - Sunedison Inc (NYSE:SUNE), Bacterin International Holdings Inc (NYSEMKT:BONE), OHR Pharmaceuticals Inc (NASDAQ:OHRP)

Watch List Highlights - Sunedison Inc (NYSE:SUNE), Bacterin International Holdings Inc (NYSEMKT:BONE), OHR Pharmaceuticals Inc (NASDAQ:OHRP)
Written by
Joel Najarian
Published on
October 14, 2014
Copy URL
Share on LinkedIn
Share on Reddit
Share on Twitter/X
Share on Facebook
InsidrFinancial

Sunedison Inc (NYSE:SUNE), the solar-technology manufacturer said the overall cap on its credit facility was doubled to $800 million from $400 million. SUNE trades in a 52-week range of $8.67 to $24.35. The credit facility was also amended to permit investments in a subsidiary of the company formed for the purpose of owning subsidiaries that own and operate renewable energy systems, and wind, biomass, natural gas, hydroelectric, geothermal or other clean-energy generation systems or hybrid energy generation systems."These increases in our credit facility will enable Sunedison Inc (NYSE:SUNE) to capture additional business opportunities and continue our rapid volume growth," said Brian Wuebbels, chief financial officer of SunEdison. Separately, the company unveiled new "zero white space" solar-module technology that it said can increase solar-module power output by up to 15%, effectively decreasing the total system cost by up to 8%. High-volume manufacturing of the technology is expected to begin in the second half of 2015, it said.Bacterin International Holdings Inc (NYSEMKT:BONE), a developer of bone graft material and coatings for medical applications, has announced preliminary, unaudited revenue for Q3 2014. Bacterin International Holdings Inc (NYSEMKT:BONE) is expecting total revenue for the third quarter of 2014 to be in the range of $8.4 million to $8.5 million, representing an increase of 6% to 7% when compared to $7.9 million in Q3 2013. The results are below the analyst estimate of $9.54 million on Capital IQ, if comparable."After meeting our goal of stabilizing the business by the end of 2013, we began investing in new products and strengthening our sales force," said Bacterin CEO Dan Goldberger. "We are now starting to realize the benefits of these investments and we expect to see our revenue accelerate by the end of 2015." Shares of BONE are at $3.77 within a 52-week range of $3.41 - $14.10.OHR Pharmaceuticals Inc (NASDAQ:OHRP), an ophthalmology research and development company, will begin Phase 3 trials in the first half of 2015 for Squalamine Eye Drops (OHR-102) in the treatment of wet age-related macular degeneration (wet AMD). The company plans a New Drug Application (NDA) following collection and analysis of the nine-month primary efficacy data.The trials are being designed based on guidance provided by the U.S. Food and Drug Administration (FDA) at a recent meeting marking the end of Phase 2. The FDA has agreed with Ohr on a nine-month primary efficacy endpoint based on the proportion of patients achieving a =3 line gain in visual acuity.The Phase 3 trials for Squalamine eye drops are being designed to measure the efficacy of combination therapy with OHR-102 eye drops plus Lucentis injections compared with Lucentis monotherapy. Shares of OHR Pharmaceuticals Inc (NASDAQ:OHRP) are at $7.37 within a 52-week range of $6.01 - $20.00.

Discover Hidden Gems

Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.